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Abstract
Salvia miltiorrhiza (Labiatae, Laminaceae), danshen, is an annual sage mainly found in China and
neighboring countries. The crude drug (dried root) and its preparations are currently used in China
to treat patients suffering from heart attack, angina pectoris, stroke and some other conditions.
The use of S. miltiorrhiza has been increasing in the management of stroke. Pharmacological
examinations showed that the plant and its active ingredients, tanshinones and salvianolic acids,
have anticoagulant, vasodilatory, increased blood flow, anti-inflammatory, free radical scavenging,
mitochondrial protective and other activities. This review discusses the pharmacology, medicinal
chemistry and clinical studies published, especially in China, for danshen  and tanshinone
preparations. Clinical examinations are evaluated in terms of S. miltiorrhiza preparation, dose,
double blinding, control, clinical assessments of outcomes and other parameters. Meta-analyses of
S. miltiorrhiza are also discussed.
Background
Danshen is an annual sage plant, Salvia miltiorrhiza (Labia-
tae, Laminaceae) which grows in China, Mongolia, Korea
and Japan. In China, it is found in hilly areas of the west,
southwest and southeast. S. miltiorrhiza is among the most
popular medicinal herbs used in China. It has been used
in the treatment of stroke since 1970 [1], angina and heart
attack, as an antihypertensive and a sedative [2]. S. miltior-
rhiza contains several compounds that are pharmacologi-
cally active, especially the diterpenoids known as
tanshinones. A related plant, Salvia columbariae, from Cal-
ifornia, USA also contains tanshinones, especially crypto-
tanshinone [3]. This plant has been used by Californian
Indians to treat people suffering from strokes [4].
S. miltiorrhiza is often used in fufang with other herbs in
Chinese herbal medicine. Fufang in Chinese herbal medi-
cine means a formula comprising multiple herbs. One of
the widely prescribed Chinese fufang for stroke patients is
30 g of the roots of Astragalus membranaceus and
Hedysarum coronarium, 10 g of cinnamon twig (Cinnamo-
mum verum), 10 g of peach kernel (Prunus persica), 10 g of
safflower (Carthamus tinctorius), 12 g of Angelica sinensis
root, 12 g of the rhizome of Ligustica chuanxiong, 12 g of
the root of Paeonia rubra, 12 g of earthworm (Lumbricus),
30 g of the root of S. miltiorrhiza and 15 g of the root of
Achyranthis bidentata [5]. The ingredients are added to
water and boiled for an hour or two until the required vol-
ume is attained. The preparation is orally administered to
the patient. Other plants can be added to this as needed
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by the patient for severe blood stasis, deficiency of qi and
some other conditions. Qi is the life force that comes from
air, food and the genetic background. The therapeutic
principle of the treatment is to supplement qi, nourish the
blood and promote blood circulation in order to remove
obstructions of the channels, which are the acupuncture
channels, not blood vessels.
Pharmacology
Danshen
S. miltiorrhiza has been shown to inhibit angiotensin con-
verting enzyme (ACE), to lower blood pressure, dilate
arteries, and to decrease blood clotting [6-9]. Inhibition of
ACE may be involved in the ability of S. miltiorrhiza to
alter angiotensin II levels, and indirectly, the levels of
atrial natriuretic peptide [10,11]. ACE inhibitors have
been extensively studied in cardiovascular disease and
have been shown in several clinical trials to decrease the
risk of suffering a primary or secondary stroke [12-14].
ACE inhibitors are known to decrease the risk of having a
stroke. Unfortunately, Western ACE inhibitor drugs have
not been tested as treatments for stroke after its occur-
rence. The primary mechanism of this protection appears
to be in lowering blood pressure. However, other mecha-
nisms are also probably involved including decreasing
clot formation by decreasing cardiac fibrillation, and
decreasing the levels of angiotensin. Angiotensin has sev-
eral potentially dangerous effects in regard to stroke,
including hypertension, increasing noradrenergic nerve
activity and blocking norepinephrine reuptake in the
brain [15]. Brain ischemia and reperfusion, during stroke,
cause the release of many neurotransmitters including
norepinephrine, in part due to ATP depletion. These neu-
rotransmitters may be damaging to the brain by inducing
excitotoxicity, by oxidizing to produce oxygen radicals or
other mechanisms. The effects of angiotensin on extracel-
lular neurotransmitter levels during ischemia and reper-
fusion in the brain could be devastating. S. miltiorrhiza has
been shown to decrease the release of norepinephrine,
dopamine and serotonin during brain ischemia [16].
Thrombosis secondary to atherosclerosis is a major cause
of stroke. Small thrombi lodge in small arteries of the
brain, especially the middle cerebral artery, and cause
ischemia. Fibrinolytic enzymes normally found in the
blood such as plasmin, break down clots within a few
hours and allow reperfusion. Clot dissolution with tissue
plasminogen activator is known to be beneficial in some
stroke patients, provided that it is used within 3 hours of
stroke. Inhibition of clot formation and potential clot dis-
solution has been demonstrated in many clinical trials of
S. miltiorrhiza as discussed below. S. miltiorrhiza has been
found to increase the proteolysis of fibrinogen to fibrino-
gen degradation products [17]. This is a unique mecha-
nism of anticoagulation in comparison to other
anticoagulant drugs that tend to prevent clot formation by
interfering with platelet function or interfering with the
action of thrombin or vitamin K. S. miltiorrhiza induced
arterial dilation in the brain could help reperfuse the brain
better allowing a faster recovery. Ischemia causes ATP and
NAD levels to decrease in the brain [18]. Reperfusion
allows oxygen to reflow into the brain and form reactive
oxygen radicals, especially when mitochondrial and cellu-
lar enzymes are not functioning efficiently due to low oxy-
gen tensions [19]. These oxygen radicals can damage
cellular macromolecules, including DNA, and induce
apoptosis and necrosis [20].
S. miltiorrhiza has other effects on stroke including anti-
inflammation, free radical scavenging, antioxidant and
mitochondrial protection effects. Tanshinone I from S.
miltiorrhiza inhibits arachidonic acid metabolism, inter-
leukin-12 production and has anti-inflammatory effects
[21,22]. Neutrophil activation is inhibited by an unspeci-
fied tanshinone [23] which is an anti-inflammatory agent.
S. miltiorrhiza antioxidant activity is also expressed as
increases in superoxide dismutase, catalase, glutathione
peroxidase and glutathione transferase activities [24,25].
Free radical scavenging and mitochondrial protective
activities of S. miltiorrhiza have been found [26-28].
Fufang danshen
Clinical trials demonstrated that fufang danshen enhanced
stroke survival and recovery in comparison to S. miltior-
rhiza alone as discussed below. The idea is that additional
herbs will synergize the desirable effects or decrease the
side effects of S. miltiorrhiza. Commercially available
fufang danshen can be in two forms, one containing S.
miltiorrhiza and jiangxiang (Dalbergia odorifera), the other
containing S. miltiorrhiza, Panax notoginseng and Ligusti-
cum wallichii. Most published clinical trials used the Dal-
bergia odorifera form of fufang danshen.
Dalbergia odorifera contains medicarpin and 6-hydroxy-2-
(2-hydroxy-4-methoxyphenyl) benzofuran(IV) that
inhibit leukotriene synthesis [29]. Dalbergia odorifera also
contains anti-inflammatory flavonoids such as (S)-4-
methoxydalbergione, cearoin, butein, koparin, bowdi-
chione, 3'-O-methylviolanone and xenognosin B [30].
Platelet aggregation and prostaglandin synthesis are
inhibited by cinnamylphenols, isoflavans, isoflavene and
a benzoic acid derivative from Dalbergia odorifera [31].
Vasorelaxant compounds are found in Dalbergia odorifera
such as butein [32] and isoliquiritigenin [33]. Panax noto-
ginseng, which contains several ginsenosides and has anti-
platelet activity [34], has been found to improve survival
in patients of cerebral trauma and cerebral ischemia reper-
fusion [35,36]. Ligusticum wallichii contains tetramethyl-
pyrazine that is protective in ischemia reperfusion injury
of the brain [37], has anti-platelet activity [38] and isChinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
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hypotensive perhaps due to calcium antagonism [39].
Ligusticum wallichii also contains ferulinolol that is a β1
blocker and a partial β2 agonist [40].
Medicinal chemistry
As S. miltiorrhiza, especially fufang danshen, have many
pharmacologically active compounds in the preparation,
one would ask which compound is the active one for
stroke and ischemic diseases. The answer is that many
active compounds in the preparations are beneficial in
stroke and ischemic diseases. Among all active com-
pounds, diterpenoids and salvianolic acid derivatives are
most studied.
The diterpenoids of S. miltiorrhiza are characterized by
tanshinones (Figure 1) and isotanshinones (Figure 2).
Miltirone, salviol (Figure 3) and other diterpenoids are
also present. Miltirone has sedative activity and is a ben-
zodiazepine receptor agonist [41]. Purified tanshinone
IIA and IIB are neuroprotective in cerebral ischemia and
reperfusion [42]. Tanshinone I, cryptotanshinone and
tanshinone V are protective against myocardial ischemia
and reperfusion [2]. Tanshinones are also anti-inflamma-
tory agents. Tanshinone I, dihydrotanshinone and crypto-
tanshinone inhibit interleukin-12 and interferon-γ
production [22]. Tanshinone I inhibits arachidonic acid
metabolism by phospholipase A2 [21].
Salvianolic acids in S. miltiorrhiza appear to be synthe-
sized from monoterpenoids such as danshensu (Figure 4).
Acetylsalvianolic acid A, a semi-synthetic derivative of
salvianolic acid from S. miltiorrhiza is neuroprotective in
middle cerebral artery thrombosis [43] and inhibits plate-
let aggregation [44]. Salvianolic acids (Figure 5) from S.
miltiorrhiza increase cerebral blood flow after ischemia
[45]. Salvianolic acid A is protective against cerebral and
myocardial ischemia and reperfusion [46]. Lithospermic
acid B (Figure 6), also called tanshinoate B or salvianolic
acid B, increases NO production by endothelial cells [47]
and inhibits ACE [6]. NO is a vasorelaxant that should
bring down local blood pressure. Lithospermic acid B is
antihypertensive and is protective against cerebral and
myocardial ischemia and reperfusion [46]. Rosmarinic
acid and salvianolic acids in S. miltiorrhiza inhibit throm-
bosis, thromboxane B2 formation and platelet aggrega-
tion [45,46].
Danshensu literally means the active ingredient in S.
miltiorrhiza and has been used to refer to different active
compounds. Early investigators identified 2-hydroxy-4-
catecholbutyric acid (Figure 4) in S. miltiorrhiza, assumed
it was the active ingredient in S. miltiorrhiza, and named
it danshensu. Later work identified tanshinone IIA as the
primary active ingredient in the treatment of ischemic dis-
eases. Most Chinese publications in the last 20 years refer
to tanshinone IIA as danshensu. As the salvianolic acids in
S. miltiorrhiza are also responsible for the effects of S.
miltiorrhiza in ischemic disorders, salvianolic acid B has
recently been referred to as danshensu as well by some
Chinese manufacturers.
Clinical trials
A chronological analysis
S. miltiorrhiza has been tested in clinical trials of ischemic
diseases such as angina, heart attack and stroke. These tri-
als have been discussed in other publications [1,2,47-50].
Time of onset of stroke or myocardial infarction is a con-
founding issue in many of the trials. It is not unusual for
clinical trials to begin treatment with S. miltiorrhiza 1 week
or more after an ischemic attack. Many Chinese patients
were treated initially (within a few hours of onset) with
the standard therapy for stroke or heart attack by local
medical personnel before admission to a hospital. In most
regions of China, the standard therapy for a heart attack or
stroke is S. miltiorrhiza. The dosage of S. miltiorrhiza is usu-
ally clearly stated in published trials.
In a 1979 publication [51] of angina pectoris, 89 male and
19 female patients aged 40–75 were studied. Tanshinone
IIA, as a sodium sulfonate salt, was injected intravenously
(IV) in doses of 80 mg per day. The study was not blinded
or randomized and had no controls. Symptoms and elec-
trocardiograph (ECG) changes were monitored. The
patients who responded to tanshinone IIA injections
within 4 treatments or less gave an overall effective rate of
86%. The authors found that tanshinone IIA gave results
similar to fufang danshen. Twelve patients with acute myo-
cardial infarction were treated with tanshinone IIA, where
improvement was found in ten cases. Tanshinone IIA pro-
duced a mild antihypertensive effect and decreased
plasma viscosity.
Chen et al. [52] published a study of fufang danshen, as
purified coronary heart II tablets, in 112 angina patients.
The tablets contained extracts of S. miltiorrhiza, Paeonia
obovata, Ligusticum wallichii, Carthamus tinctorius and Dal-
bergia odorifera. The doses of each ingredient were not
stated. The study was randomized, double blinded and
placebo controlled. Improvements were recorded in terms
of clinical symptoms and ECG improvements. S. miltior-
rhiza was 80% effective compared to a 16% effective rate
for the placebo.
A study was published in 1991 concerning the use of S.
miltiorrhiza in 120 stroke patients [53]. The study was ran-
domized, but not blinded or placebo controlled. There
were 96 male and 24 female patients between the ages of
50 and 84. The patients either had strokes (86 cases) or
transient ischemic attacks (14 cases). They were adminis-
tered S. miltiorrhiza containing 40 mg of tanshinone IIA inChinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
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Tanshinones found in S. miltiorrhiza Figure 1
Tanshinones found in S. miltiorrhiza. All of these compounds contain benzoquinone functionalities.
O
O
O
O
O
O
O
O
O
CH2OH
O
O
O
O
O
O
O H
O
O
O
O
O
OH
O
O
O
Tanshinone IIA
Tanshinone I
Cryptotanshinone
Tanshinone IIB
Hydroxytanshinone IIA Methyl tanshinonate
Miltionone II
O
O H
OH
O
O
Tanshindiol BChinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
Page 5 of 15
(page number not for citation purposes)
either a 40 ml injection or a 500 ml IV drip. The time of
administration after the ischemic attack ranged from 3–10
hours in the transient ischemic attack cases, or 1–15 days
in the stroke cases. The S. miltiorrhiza preparations were
88% effective in alleviating the symptoms of ischemic dis-
eases. It was claimed that the 40 ml injection form was
better than the 500 ml IV drip form of S. miltiorrhiza.
A study of subarachnoid bleeding in 42 patients was pub-
lished in 1992 [54]. There were 18 male and 24 female
patients. Two patients were younger than 50. Thirteen
patients were between 51 and 60 years old. Twenty one
patients were older than 61. The study was not rand-
omized, blinded or placebo controlled. The time of
administration of S. miltiorrhiza ranged from 3 to 7 days
after onset. The S. miltiorrhiza group of 42 patients
received IV S. miltiorrhiza containing 25 – 75 mg of tanshi-
none IIA, daily for 3 weeks. The control group of 38
patients received 24 g of 6-aminocaproic acid (a hemo-
static agent) each day for 3 weeks. The intracranial pres-
sure of each patient was monitored and corrected with
125 – 250 ml of 20% mannitol daily for 7 – 10 days. High
intracranial pressure was above 23.51 kPa. Clinical symp-
toms and blood in the cerebrospinal fluid were assessed in
each patient. S. miltiorrhiza was 95% effective compared to
79% efficacy in the control group. S. miltiorrhiza cleared
hemoglobin from the cerebrospinal fluid within 3 weeks,
whereas 4 weeks were required in the control group.
Fufang danshen containing Dalbergia odorifera was used in
a study of 95 patients with bland or hemorrhagic stroke
[55]. Patients were 38 – 72 years old. The study was not
randomized, blinded or placebo controlled. Forty two
patients were treated daily with IV fufang danshen contain-
ing 100 mg of tanshinone IIA. Fifty three patients were
treated daily with fufang danshen containing 50 mg of tan-
Isotanshinones found in S. miltiorrhiza Figure 2
Isotanshinones found in S. miltiorrhiza. All of these compounds contain naphthoquinone groups.
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shinone IIA. The treatment period ranged from 1 to 4
weeks. Patients were assessed in terms of symptom
improvement. A standard format of clinical assessment
was adopted in China at this time. The treatment was
described as a cure, very effective, effective, not effective or
the treatment made symptoms worse. High dose treat-
ments resulted in a 95% total effective rate. Low dose
treatments were 79% totally effective. The total effective
rate is derived by adding the numbers of patients from the
cure, very effective and effective groups.
Thirty stroke patients were studied for quality of life
improvements after stroke treatment with fufang danshen
[56]. There were 20 male and 10 female patients of aver-
age age 64. The study was not randomized, blinded or pla-
cebo controlled. Fufang danshen was administered daily
into the carotid artery, on the affected side, in doses that
contained 10 mg of tanshinone IIA. Treatments started 2
to 77 days after stroke. Patients were assessed in terms of
CT brain scans, paralysis, independent living and other
quality of life measurements. The effective rate was 97%.
Fifty six patients suffering from angina or angina associ-
ated with previous myocardial infarction were studied in
a 1997 article [57]. There were 38 male and 18 female
patients aged 39 – 68. Thirty three patients had angina
alone. Twenty three patients suffered from angina and
had previous myocardial infarctions. All patients were
evaluated in terms of clinical symptoms and ECG
changes. The study was not randomized, blinded or pla-
cebo controlled. Fufang danshen containing Dalbergia odor-
ifera was administered in IV doses containing 40 – 80 mg
of tanshinone IIA. The drug was given daily over a period
of 14 – 30 days. Standard drugs used in heart disease, such
as dipyridamole, were not discontinued. S. miltiorrhiza
was found to be 89% effective at improving angina parox-
ysms. It was 67% effective at improving conductance in
the heart as indicated by ECG changes.
Cor pulmonale was examined in 52 patients [58]. There
were 24 male and 28 female patients. The average age of
the patients was 78. There were two treatment groups,
fufang danshen and routine Western therapy. Fufang dan-
shen was administered to 31 patients. The Western therapy
group included 21 patients. The study was blinded but not
randomized. Fufang danshen with Dalbergia odorifera was
administered in IV doses containing 50 mg of tanshinone
IIA daily for 7 – 10 days. Western therapy included cardi-
Miltirone and salviol from S. miltiorrhiza Figure 3
Miltirone and salviol from S. miltiorrhiza. These compounds contain phenol or benzoquinone groups.
O
O
Miltirone
OH
O H
SalviolChinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
Page 7 of 15
(page number not for citation purposes)
otonics, diuretics and other drugs. Patients were evaluated
in terms of breathing, heart function, edema, arrhythmias
and other symptoms. S. miltiorrhiza was found to be 87%
effective. Western therapy was 62% effective. S. miltior-
rhiza was significantly better than Western therapy.
A 1997 publication discussed several clinical trials of S.
miltiorrhiza [59]. None of the trials appear to be rand-
omized, blinded or placebo controlled. A study of sub-
arachnoid cavity bleeding administered IV S. miltiorrhiza
in doses containing 100 mg of tanshinone IIA to 24
Danshensu and monoterpenoids from S. miltiorrhiza Figure 4
Danshensu and monoterpenoids from S. miltiorrhiza. All of these compounds contain catechol functionalities.
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patients daily for 10 days. Patients were also treated with
anti-hypertensives and vasodilators as needed. High
intracranial pressure was treated with IV infusions of 20%
mannitol or 50% glucose 3 – 4 times a day for 3 – 5 days.
Twenty three patients improved. One patient died. A
study of 48 patients suffering from cerebral thrombosis
was discussed. S. miltiorrhiza was administered daily in IV
doses containing 75 mg of tanshinone IIA. The discussion
Salvianolic acids from S. miltiorrhiza Figure 5
Salvianolic acids from S. miltiorrhiza. All of these compounds contain catechol moieties.
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Lithospermic acids from S. miltiorrhiza Figure 6
Lithospermic acids from S. miltiorrhiza. Each of these compounds contains two or more catechols.
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indicated that S. miltiorrhiza was effective at reducing the
sequelae of cerebral thrombosis. A study of angina
patients compared pentaerythritol tetranitrate to the com-
bination of S. miltiorrhiza and pentaerythritol tetranitrate.
Patients were assessed for clinical improvement and ECG
changes. The combination of S. miltiorrhiza and pentaer-
ythritol tetranitrate was significantly better than pentaer-
ythritol tetranitrate alone.
S. miltiorrhiza has been manufactured in several pill forms,
such as composite danshen droplet pills [60]. The amount
of tanshinone IIA in these pills is not published. A trial of
these pills was randomized, blinded and placebo control-
led. The danshen droplet pills were described as effective in
the treatment of angina and more effective than placebo.
After 1997, many studies were published comparing S.
miltiorrhiza  to other herbal preparations. S. miltiorrhiza
had become the standard therapy for stroke and other
ischemic conditions in China. All new preparations had
to be compared to S. miltiorrhiza. A 1998 study compared
S. miltiorrhiza to a combination of S. miltiorrhiza and
huangqi [61]. Huangqi is Astragalus membranaceus and is
used to reestablish qi. Astragalus membranaceus contains
several glycosides, including astragaloside IV that is neu-
roprotective in a stroke model [62,63]. The S. miltiorrhiza
alone group contained 78 patients of average age 68. All
patients had suffered from strokes 1 – 10 days before
admission to the study. S. miltiorrhiza was given IV in
doses containing 40 mg of tanshinone IIA twice a day for
28 days. The trial was not randomized, blinded or placebo
controlled. Patients were assessed for hematocrit, blood
viscosity and other parameters. S. miltiorrhiza was 69%
effective. Astragalus membranaceus improved the efficacy of
S. miltiorrhiza.
A later study re-evaluated Astragalus membranaceus and S.
miltiorrhiza in stroke [64]. Twenty patients were treated
with S. miltiorrhiza alone in IV doses containing 40 mg of
tanshinone IIA daily for 20 days. The time of administra-
tion after stroke was not specified. The trial was not
blinded, randomized or placebo controlled. Patients were
evaluated for neurological status and plasma levels of
prostaglandin I2 and thromboxane A2. S. miltiorrhiza pro-
vided a 75% improvement in clinical status, increased
prostaglandin I2 levels and decreased thromboxane A2 lev-
els. The combination of Astragalus membranaceus and S.
miltiorrhiza  was found to be superior to S. miltiorrhiza
alone.
A 1999 publication compared S. miltiorrhiza to an unspec-
ified anti-thrombotic enzyme [65]. Patients were older
than 75, had suffered from strokes that impaired con-
sciousness, had atrial fibrillation and a history of hemor-
rhage. The treatment group received the anti-thrombotic
enzyme. The control group was administered IV S. miltior-
rhiza containing 50 mg of tanshinone IIA. Drug adminis-
tration occurred as soon as possible after stroke, from 6 to
> 48 hours after stroke. The trial was not blinded, rand-
omized or placebo controlled. S. miltiorrhiza alone, given
within 6 hours after stroke, was 55% effective in terms of
improving neurological functions. The anti-thrombotic
enzyme was 90% effective when administered within 6
hours after a stroke.
S. miltiorrhiza was compared to naloxone in a trial of
patients who remained unconscious after stroke [66]. The
group that received S. miltiorrhiza alone included 35
patients of average age 61. There were 21 males and 14
females. S. miltiorrhiza or naloxone was administered as
soon as possible after stroke in unspecified doses. The trial
was not randomized, blinded or placebo controlled. S.
miltiorrhiza was 74% effective at improving neurological
functions. Patients regained consciousness in 36 ± 16
hours after admission to the study. Naloxone appeared to
be more effective than S. miltiorrhiza.
A later study recompared naloxone and S. miltiorrhiza in
stroke patients [67]. Ninety six stroke patients were ran-
domly assigned to S. miltiorrhiza or naloxone groups. The
study was not blinded or placebo controlled. Fufang dan-
shen was administered in doses containing 40 mg of tan-
shinone IIA, daily for 10 days. Naloxone was given in
doses of 2 mg per day for 10 days. Patients were assessed
for improvement of neurological symptoms. The S. milti-
orrhiza  group demonstrated 58.3% improvement.
Naloxone treated patients had a 92% improvement in
symptoms.
S. miltiorrhiza was also compared to naloxone in heart
attack patients [68]. The study was not randomized,
blinded or placebo controlled. Seventy two patients were
given either naloxone 0.8 g per day for 5 days or fufang
danshen containing 50 mg of tanshinone IIA daily for 5
days. Symptoms and hemorrheological parameters were
assessed. S. miltiorrhiza was 89% effective compared to
75% efficacy for naloxone. Fufang danshen decreased
blood viscosity and fibrinogen content. The side effects of
fufang danshen were nausea, vomiting and facial flushing.
Nicergoline, an ergot alkaloid, was compared to S. miltior-
rhiza in patients suffering from acute stroke [69]. The trial
was randomized, but not blinded or placebo controlled.
S. miltiorrhiza alone was administered daily for 15 days in
IV doses containing 50 mg of tanshinone IIA to 50
patients. The time of administration after stroke was not
specified. Patients were assessed for neurological status
and cerebral blood flow. S. miltiorrhiza was 72% effective
at improving neurological status and improved cerebral
blood flow to some extent. The combination of nicergo-Chinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
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line and S. miltiorrhiza was reported to be superior to S.
miltiorrhiza alone.
Prostaglandin E1 was compared to S. miltiorrhiza in a trial
of acute stroke patients [70]. Patients were treated soon
after stroke with IV prostaglandin E1 (200 μg) or IV S.
miltiorrhiza containing 40 mg of tanshinone IIA. S. miltior-
rhiza was administered daily for 15 days. The trial was not
randomized, blinded or placebo controlled. S. miltiorrhiza
was 90% effective at improving neurological status,
decreased blood viscosity, cholesterol and triglycerides.
Prostaglandin E1 treatment was as effective as S. miltior-
rhiza treatment.
Several trials have compared S. miltiorrhiza to other Chi-
nese herbal medicines, such as honghuayou  and  gegen.
Honghua is Carthamus tinctorius also known as safflower.
Safflower oil, honghuayou in Chinese, is used in the treat-
ment of ischemic conditions. Gegen is Pueraria lobata. A
comparison of honghua and S. miltiorrhiza was performed
in 60 patients in randomly assigned groups [71]. The
study was not blinded or placebo controlled. Patients
were treated within 72 hours of stroke. The Carthamus
tinctorius oil group received 20 ml of safflower oil in 500
ml of 5% glucose solution, daily. The fufang danshen
group received daily doses containing 50 mg of tanshi-
none IIA in a solution of low molecular weight glycogen.
There were 30 patients, 18 males and 12 females, of aver-
age age 59 in the gegen group. The fufang danshen group
had 17 male and 13 female patients of average age 59.
Patients in both groups were treated for 14 days and eval-
uated for neurological symptoms. The Carthamus tinctorius
effective rate was 93% compared to 90% for fufang dan-
shen. Another stroke study [72] of Carthamus tinctorius oil,
40 ml, and S. miltiorrhiza, 40 mg of tanshinone IIA, exam-
ined 36 Carthamus tinctorius oil patients and 32 S. miltior-
rhiza patients. The study was not blinded, randomized or
placebo controlled. Carthamus tinctorius was 95% effective
and significantly more effective than S. miltiorrhiza, 84%.
Both groups experienced reduced blood viscosity and
blood fat. A Pueraria lobata study in 60 stroke patients
administered 500 mg of gegensu (Pueraria lobata factor) to
18 male and 12 female patients [73]. Fufang danshen was
administered in doses containing 50 mg of tanshinone IIA
to 19 male and 11 female patients. The study was not ran-
domized, blinded or placebo controlled. Patients were
treated daily for 14 days then evaluated for neurological
symptoms and by CAT scan. Pueraria lobata was 70% effec-
tive compared to 33% for S. miltiorrhiza.
S. miltiorrhiza has been compared to oxygen in the treat-
ment of 102 stroke patients [74]. The study was not
blinded, randomized or placebo controlled. Patients had
suffered from strokes 30 minutes to 48 hours prior to
being admitted to the study. CAT scan analysis showed
blocked blood flow in the brains of the patients. S. milti-
orrhiza was administered IV to 34 male and 18 female
patients of average age 58 in doses containing 50 mg of
tanshinone IIA. This group of patients also received oxy-
gen by face mask for 1 hour daily for 10 days. The second
group of 31 male and 19 female patients of average age 57
received only S. miltiorrhiza. Patients were assessed for
neurological symptoms, blood flow, blood viscosity, clot-
ting and sedimentation rate 10 days after admission. Both
therapies were 100% effective. S. miltiorrhiza with oxygen
produced a cure rate of 23%, in other words no residual
neurological symptoms. S. miltiorrhiza alone produced a
cure rate of 18%.
Acuthrombin-B, an enzyme with thrombin-like activity
from the venom of Deinagkistrodon acutus the hundred
pace pit viper, has been compared to S. miltiorrhiza in
stroke patients [75]. The study was not randomized,
blinded or placebo controlled. Sixty two patients, 38
males and 24 females of average age 62, were IV adminis-
tered 0.75 U of snake enzyme daily for 7 days. The fufang
danshen group of 39 males and 23 females of average age
63, were given IV S. miltiorrhiza containing 40 mg of tan-
shinone IIA daily for 14 days. At 14 days the patients were
assessed for neurological symptoms. The total effective
rate for acuthrombin-B was 85% compared to 68% for S.
miltiorrhiza.
A study of patients undergoing cardiopulmonary bypass
procedures examined the effects of S. miltiorrhiza on
endothelin, prostaglandins and thromboxanes [76].
Endothelin is a vasoconstrictor peptide found in the body.
The study was not randomized or blinded. The treatment
group consisted of 10 patients treated with 200 mg/kg of
tanshinone IIA immediately after surgery. The placebo
control group of 10 patients received saline. Endothelin
decreased while prostaglandin I2 (PGI2) and thrombox-
ane A2 (TXA2) increased in both groups during surgery.
Endothelin increased from 30 minutes to 24 hours after
reperfusion. The increase in endothelin was less in the
tanshinone group than the placebo group. PGI2 and TXA2
decreased during reperfusion. The tanshinone group had
a more rapid decrease in these factors while the ratio of
PGI2/TXA2 was higher than the placebo group. These fac-
tors are involved in control of vascular tone and platelet
aggregation that are critical to patients suffering from
ischemic conditions.
Buflomedil, an α1A  receptor blocking vasodilator, has
been compared to S. miltiorrhiza in stroke patients, with-
out intra-cerebral hemorrhage [77]. The patients were ran-
domly assigned to buflomedil or S. miltiorrhiza groups.
The study was not blinded or placebo controlled. Buflo-
medil, 200–300 mg, or fufang danshen, containing 50 mg
of tanshinone IIA were administered daily for 14 days.Chinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
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The buflomedil group contained 30 males and 12 females
of average age 58. The S. miltiorrhiza group contained 32
males and 13 females of average age 56. On day 15,
patients were evaluated for neurological symptoms.
Buflomedil was 90% effective. S. miltiorrhiza was 69%
effective and significantly decreased blood viscosity.
A study of 100 angina patients compared two pill forms of
S. miltiorrhiza, Coronary Heart Radix Salvia Miltiorrhiza
Drop Pill and Coronary Heart Radix Salvia Miltiorrhiza
Tablet [78]. The study was blinded and randomized but
not placebo controlled. Both pills were administered sub-
lingually. The drop pill contained 0.065 mg of salvianolic
acid B per pill and was used in doses of 10 pills 3 times
daily, except during angina attacks when 15–20 pills were
used. The tablet contained an unspecified amount of tan-
shinone IIA and was used in doses of 3 pills 3 times daily,
except during angina attacks when the dose increased to
4–5 pills. Both pills improved chest pain, ECG changes
and decreased blood viscosity. The drop pill was 93%
effective. The tablet was 88% effective.
Carnitine was compared to S. miltiorrhiza in a study of 135
patients [79]. The study was not randomized, blinded or
placebo controlled. Patients had suffered from strokes
within 7 days of admission to the study. Thirty seven male
and 31 female patients were administered 1 g of carnitine
IV daily for 28 days. Thirty nine male and 28 female
patients were given IV fufang danshen containing 50 mg of
tanshinone IIA daily for 28 days. Carnitine produced a
99% effective rate, while S. miltiorrhiza was 65% effective
at improving neurological symptoms.
A study of S. miltiorrhiza in 68 stroke patients adminis-
tered composite salvia injection in unspecified doses [80].
The patients were randomly divided into groups that
received either S. miltiorrhiza or a control medicine
referred to as xueshuantong  (embolism medicine). The
total effective rate of S. miltiorrhiza was 88%. The placebo
effective rate was not reported.
Tanshinone IIA was administered in daily doses of 1 g to
patients who had suffered strokes from 1 month to 2 years
previously [81]. All patients had persistent symptoms of
stroke such as paralysis, low muscle strength, movement
problems, speech difficulty and memory impairment.
Tanshinone IIA was compared to yang 5 ingredient soup.
The decoction contains Angelica sinensis, Prunus persica,
Tagetes erecta, Ligusticum wallichii, S. miltiorrhiza, Paeonia
lactiflora,  Pherectima aspergillum and  Astragalus mem-
branaceus. The study was not blinded, randomized or pla-
cebo controlled. Tanshinone IIA was given 3 times daily
IV for 4 weeks. Yang 5 ingredient decoction was given
orally, 200 ml, twice daily for 4 weeks. Patients were then
assessed for muscle strength in the arms, legs and abdo-
men. Tanshinone IIA was 96% effective and cured 21% of
patients. Yang 5 ingredient decoction was 59% effective
and cured 12% of patients of stroke symptoms.
Pregnancy induced hypertension was investigated in 60
patients [82]. The study was not blinded, randomized or
placebo controlled. S. miltiorrhiza injection containing 40
mg of tanshinone IIA was administered daily for 10 days.
S. miltiorrhiza decreased blood viscosity, cholesterol and
lipoprotein levels.
A study of 120 stroke patients compared S. miltiorrhiza
and defibrase, which was not identified but may be a
snake venom fibrin cleaving enzyme [83]. The study was
not randomized or blinded. S. miltiorrhiza was used as the
control. S. miltiorrhiza containing 50 mg of tanshinone IIA
was administered IV daily for 14 days to one third of the
patients. The effective rate of S. miltiorrhiza was 78%. S.
miltiorrhiza  also improved neurological symptoms 3
months after administration but did not alter carotid
artery atherosclerosis.
Percutaneous coronary intervention and the effects of
fufang danshen were studied in 38 myocardial infarction
patients [84]. The study was randomized but not blinded.
Control patients received no fufang danshen. This fufang
danshen  contained  Panax ginseng, Schisandra berry and
Ophiopogonis as well as S. miltiorrhiza. All patients received
percutaneous coronary intervention. Left ventricular func-
tion and various indications of oxidative damage
improved more in the fufang danshen group than the con-
trol group.
Blood coagulation was investigated in 64 traumatic brain
injury patients [85]. The study was randomized, not
blinded but was placebo controlled. The treatment group
received an unspecified dose of S. miltiorrhiza as well as
conventional Western medicine. The placebo group
received conventional Western medicine. S. miltiorrhiza
improved the neurological status of patients as well as
blood coagulation factors such as plasma P selectin, von
Willebrand's factor and D dimer.
Limitations of the trials
Time of treatment after stroke, dose, type of fufang, rand-
omized design, placebo controls and difficulty in finding
the published trials are some of the problems encoun-
tered with these trials. Time of treatment after onset of
ischemia varies from a few hours to many days. Yet
improvements have been noted in several studies when S.
miltiorrhiza was started many days after an ischemic event
such as a stroke. These results imply that S. miltiorrhiza
may stimulate brain repair mechanisms, perhaps by stim-
ulating stem cell growth, neurotrophin release or other
mechanisms. The dose of tanshinone IIA has been foundChinese Medicine 2006, 1:3 http://www.cmjournal.org/content/1/1/3
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and reported above for most of the trials. However, some
of the trials did not give enough information to allow cal-
culation of tanshinone IIA doses. The fufang danshen used
in published trials is usually the type containing Dalbergia
odorifera. However, some trials did not give enough infor-
mation to allow identification of the type of fufang used.
Few of the published trials were randomized or blinded.
This makes bias in patient selection a possibility. Few of
the published trials were placebo controlled. This makes
comparison impossible between the effects of S. miltior-
rhiza and those of other therapies in stroke. After S. milti-
orrhiza was accepted as the standard for the treatment of
stroke, S. miltiorrhiza became the control for other trials.
It is difficult, in the USA, to obtain copies of some of the
published trials. The current study found publications for
33 clinical trials of S. miltiorrhiza. There are many more tri-
als referred to in the Chinese literature but not easily
accessable. The open exchange of the information about
clinical trials should be improved.
Meta-analyses
Meta-analyses help justify the collection of data from dif-
ferent studies into one analysis. Three meta-analyses of S.
miltiorrhiza  have been published [1,45,46]. Two of the
meta-analyses found that insufficient evidence has been
published from randomized, blinded, placebo controlled
trials to support the efficacy of S. miltiorrhiza in stroke. The
other meta-analysis found that there was no evidence to
suggest that S. miltiorrhiza is effective against the disability
caused by stroke. Meta-analysis cannot be conclusive as
there is a huge variation in the design of clinical trials.
Given the discussion presented above of 33 clinical trials
of S. miltiorrhiza, it is obvious that few of the studies are
similar enough to justify collecting all their data into one
analysis. However, S. miltiorrhiza has been found to bene-
fit stroke patients, as well as angina and other patients, in
every published trial. There is a great danger of ignoring
an obvious effect of S. miltiorrhiza when meta analysis
cannot be used successfully. Since 1997, when S. miltior-
rhiza  became the common medication for stroke in
China, 17 reports of clinical trials have been published on
the use of S. miltiorrhiza in stroke. All these trials found
that  S. miltiorrhiza improved quality of life in stroke
patients.  S. miltiorrhiza was found to be effective at
decreasing the neurological symptoms of stroke in a range
of 33% – 100%, with a mean of 74%. It may be a mistake
to assert that S. miltiorrhiza has no efficacy in treating
stroke.
Discussion
The main approach of Western medicine is preventing
stroke. There is sometimes an effort made by primary care
physicians to encourage patients to lose weight and exer-
cise as preventive medicine against stroke. Anticoagulants
and aspirin are sometimes recommended to prevent clots
that may cause strokes. In the USA, stroke is treated with
tissue plasminogen activator 3 hours after stroke in a
minority of eligible patients. The remaining, ineligible
patients are usually not attended to until 6 hours after
stroke. This is when the neurological scores tend to stabi-
lize, as the stroke damage matures in the brain. However,
other than tissue plasminogen activator, there is no effort
to treat stroke patients with drugs that might enhance
their survival or recovery.
The herbal approach to stroke treatment is to find a plant
or combination of plants that helps patients survive and
recover from stroke. The drug approach involves finding a
single drug and a single mechanism to treat stroke. This is
driven by the US Food and Drug Administration require-
ments for drug approval. However, this single minded
approach may explain why no effective treatment of
stroke exists in the USA. It may be that multiple mecha-
nisms must be exploited simultaneously in order to amel-
iorate stroke symptoms. There is evidence in a stroke
model that using drugs with two different mechanisms
together can enhance stroke survival and recovery [86].
Conclusion
S. miltiorrhiza is a very useful herb in the treatment of car-
diovascular disorders. It has been extensively studied in
clinical trials in China. Most of the clinical trials have
some limitations. However, taken as a whole, the clinical
trials present compelling evidence of the efficacy of S.
miltiorrhiza in stroke, heart attack and other conditions.
Further research is needed to understand all actions of S.
miltiorrhiza, and all active compounds found in the plant,
in treating cardiovascular diseases. Research is also
needed to help us understand the pharmacological effects
of other herbs added to S. miltiorrhiza.
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